comprehensive -WSS

comprehensive

author：entertainment 2025-09-27 09:58:03 - browse：23778

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： First Opinion Podcast: How to protect health care in times of war

WSS

AstraZeneca loses challenge to Medicare drug price negotiation

First Opinion Podcast: How to protect health care in times of war

How to fix the rural physician shortage in the U.S.

FogPharma raises $145 million in rare Series E round

FogPharma raises $145 million in rare Series E round

International team creates first chimeric human

leisure time

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

23andMe had bad news about my health. I wish a person had delivered it

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Alkermes shareholders re

Physician subsidies by hospitals soar in wake of No Surprises Act

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA does about

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

CDC recommends rationing of RSV shot due to shortages

Tori Bowie and the unacceptable rates of Black maternal death

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

leisure time

Why getting cancer drugs just got harder for rural patients

Emergency medicine has repudiated 'excited delirium.' Now what?

Testing for cancer recurrence creates a new limbo for patients

RSV vaccines may be linked to small increased risk of developing GBS

Eli Lilly to pay $200M for Beam’s stake in gene

Obesity now affects over 1 billion people worldwide, study finds

focus

focus

focus

Wikipedia